Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

(1) POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 12, 2026; (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEES

POLL RESULTS OF THE EGM

References are made to the notice (the "**Notice**") of the 2026 first extraordinary general meeting and the circular (the "**Circular**") of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (百奧賽圖(北京)醫藥科技股份有限公司) (the "**Company**"), both dated January 27, 2026. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Notice and the Circular.

The Board hereby announces that the EGM was held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Thursday, February 12, 2026 at 2:00 p.m. (Hong Kong Time). The EGM was held in accordance with the requirements of the Company Law of the PRC and the Articles of Association.

As at the date of the EGM, the total number of issued shares of the Company was 446,898,420 (excluding treasury shares, if any), comprising 110,781,920 H Shares and 336,116,500 A Shares, all of which entitled the Shareholders to attend the EGM and vote for or against or abstain from voting on the resolution (the "**Resolution**") proposed at the EGM. The Company did not hold treasury shares and no voting rights of treasury shares has been exercised at the EGM. The trustees of the share award scheme of the Company holds an aggregate of 3,422,358 unvested Shares (comprising (i) the underlying Shares of the granted share awards which remain unvested; and (ii) such other Shares held for future grant of share awards) with voting rights attached (representing approximately 0.77% of the number of the issued Shares) had abstained from voting on the Resolution at the EGM. To the best knowledge, information and belief of the Company, save as disclosed above, (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the Resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the Resolution proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on the Resolution proposed at the EGM. The Resolution was put to vote by way of poll.

A total of 718 Shareholders and their proxies holding an aggregate of 264,287,036 Shares with voting rights, representing 59.1% of the total number of the voting Shares attended the EGM. Dr. Shen Yuelei, the chairman of the Company, acted as the chairman of the EGM and presided over it. All the Directors, senior management of the Company as well as the secretary of the Board were present at the meeting either in person or by means of telecommunication. The EGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results are lawful and valid.

At the EGM, Dr. Shen Yuelei, Ms. Li Yan, a lawyer from Zhong Lun Law Firm and Tricor Investor Services Limited (the H Share Registrar of the Company) were responsible for vote counting and acted as the scrutineer thereof. The poll results of the EGM were as follows:

Ordinary Resolution		**Number of Votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the proposed appointment of Mr. Liu Hongkang (劉弘康先生) as a non-executive director of the Company.	264,269,857 (99.9935)%	1,500 (0.0006)%	15,679 (0.0059)%

As more than half of the votes from the Shareholders (including their proxies) attending the EGM, with voting rights, were cast in favor of the Resolution above, the Resolution was duly passed.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Following the approval by the Shareholders at the EGM, Mr. Liu Hongkang (劉弘康先生) ("**Mr. Liu**") has been appointed as a non-executive Director, with effect from February 12, 2026 until the expiry of the term of office of the second session of the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board considered and approved the appointment of Mr. Liu as a member of the audit committee and the strategy development committee of the Board at the Board meeting held on January 27, 2026, subject to the approval of the appointment as a non-executive Director by the Shareholders. The term of office shall commence from the date of approval of the election of Mr. Liu as a non-executive Director of the second session of the Board until the expiry of the term of the second session of the Board.

WITNESS BY LAWYERS

Zhong Lun Law Firm, the Company's PRC legal adviser, considers that the convening and holding procedures of the EGM complied with the relevant requirements of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Rules for General Meetings of Listed Companies and other laws, regulations and normative documents and the Articles of Association. The qualifications of the attendees and the convener of the meeting were legal and valid, and the voting procedures and voting results of the meeting were legal and valid.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, February 12, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Mr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.